← Leaderboards
Rupal S Bhatt
Beth Israel Deaconess Medical Center
$4,031,591
Attributed
$4,031,591
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $965K · FY2010–20$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$4,031,591 · 4
By mechanism
R01$1,978,183 · 1
P50$1,205,608 · 2
K08$847,800 · 1
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Bjorn R Olsen$23,352,119
- Harold Fisher Dvorak$13,877,917
- David McDermott$9,360,637
- Laura E Benjamin$10,185,711
- Huiyan Zeng$2,837,132
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMolecularTumorRenal Cell CarcinomaReceptorAngiogenesis InhibitorsTherapy ResistantLeadPathway InteractionsNeoplastic CellProductionResistanceCombatReceptor InhibitionEventInhibitor/AntagonistPreventBlood FlowAngiogenesisIn VivoResponseMouse ModelSmall Hairpin RnaTumor Growth
Grant awards (12)
DF/HCC Kidney Cancer SPORE Tissue, Acquisition, Pathology and Clinical Data Core 2$626,676
P50 · FY2020 · CA · contact PI
Tissue Acquisition Pathology and Clinical Data$578,932
P50 · FY2019 · CA · contact PI
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma$386,083
R01 · FY2019 · CA · contact PI
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma$398,025
R01 · FY2018 · CA · contact PI
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma$398,025
R01 · FY2017 · CA · contact PI
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma$398,025
R01 · FY2016 · CA · contact PI
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma$398,025
R01 · FY2015 · CA · contact PI
Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC$169,560
K08 · FY2014 · CA · contact PI
Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC$169,560
K08 · FY2013 · CA · contact PI
Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC$169,560
K08 · FY2012 · CA · contact PI
Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC$169,560
K08 · FY2011 · CA · contact PI
Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC$169,560
K08 · FY2010 · CA · contact PI